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A major és minor depresszió prevalenciája Parkinson-kór-
ban szenvedôk között körülbelül 30-40%, ugyanakkor a
depresszió ebben a betegcsoportban aluldiagnosztizált és
alulkezelt kórkép. A depresszió diagnózisának és az adekvát
kezelésének elmaradása nemcsak a depressziós tünetek
perzisztálásához, de csökkent életminôséghez, az alap-
betegség súlyosabb tüneti képéhez és kedvezôtlenebb
prognózisához is vezetnek. Összefoglaló tanulmányunkban
a Parkinson-kórban megjelenô depresszió epidemiológiai,
patofiziológiai és terápiás vonatkozásait tárgyaljuk.
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The prevalence of major and minor depression in
Parkinson’s disease is around 30–40% but, unfortunately,
depression remains frequently underrecognized and often
undertreated. However, recognition and appropriate treat-
ment of depression in patients with Parkinson’s disease is
essential for improving the cross-sectional picture and longi-
tudinal course. This review focuses on the epidemiology,
pathophysiology and different treatment modalities of
depression in Parkinson’s disease.
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Parkinson’s disease (PD) is among the most com-mon and serious neurological disorders of later
life (median age of onset is 60 years), with an esti-
mated lifetime risk of 1.5%. The incidence of PD
increases as the age of the investigated population
is higher (50–59 yrs: 17.4/100 000/year; 70–79 yrs:
93.1/100 000/year)1–3.
The typical neurological manifestations of PD
(4–6 Hz rest tremor, muscular rigidity, hypo- and
bradykinesia and postural instability) as well as
other associated symptoms (festinant gait; marked
fatigue; masklike/expressionless face; dementia;
monotonous and slightly slurred speech; dysautono-
mia etc.) lead to a serious disability and/or reduced
quality of life (QoL), particularly in the late stage
of the illness1. PD is a true neuropsychiatric disor-
der since various psychiatric symptoms as well as
well-defined ICD–10 or DSM–IV psychiatric syn-
dromes (depressive disorders, anxiety, dementia
and psychotic disorders) can be seen in a substan-
tial proportion of patients1, 4–6.
The most common psychiatric illness associated
with PD is depression. Comorbid depression wors-
ens the cross-sectional clinical picture and outcome
and makes the treatment of PD more difficult.
Unfortunately, depression in PD patients is fre-
quently unrecognised and untreated. However,
depression associated with PD is treatable and the
successful treatment enhances not only the QoL of
the patients but also the patients’ compliance with
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the therapy and the adaptive coping strategies with
the medical illness7–13.
The unipolar or bipolar nature of depression in
patients with PD is not clear. Well-designed epi-
demiological studies on the distribution of unipolar
major depression and bipolar depression in such
patients are still lacking. Since only a few case
reports may be found in the literature on the bipolar
nature of mood disorder in PD patients it is proba-
ble that the vast majority of PD patients with
depressive symptoms suffer from unipolar depres-
sion14–16. It is interesting to note that some case-his-
tories reported on remission of Parkinsonian symp-
toms when patients become manic15, 16. Another
point where bipolar phenomenology is also linked
to PD based on clinical observations on the appear-
ance of maniac symptoms in some cases after using
some pharmacological agents (levodopa; bromo -
crip tine; selegiline, pramipexole) or deep brain
stimulation of the subthalamic nucleus (STN-DBS;
a widely used therapy for PD)7, 17, 18.
Prevalence, clinical characteristics and
consequences of depression in
Parkinson’s disease
PD and depression co-occur together much more
frequently than it would be expected by chance.
Reviewing 26 studies published between 1922 and
1990, Cummings (1992) reported that a mean rate
of depression in PD was 40% (range: 4–70%)9.
Considering only the nine studies published bet -
ween 1987 and 1990, the rate of depression ranged
from 25 to 70%, and the mean figure was 43%9.
Cummings also noted that the lowest reported fig-
ures were found in studies that were done before
standardised methodology or operationalised diag-
nostic criteria were in general use9. Most recent
reviews also show that major depression associated
with PD is quite frequent and affects 17–40% of the
patients and frequently antedates the movement dis-
order and if minor depression or dysthymic disor-
der are also considered the rate of depression in PD
raises up to 50 percent13, 19–22. Authors of one of
these recent reviews of prevalence studies observed
that prevalences were significantly lower in popu-
lation studies than in studies conducted in outpati-
ent or inpatient samples and that those studies mea-
suring the prevalence of major depressive disorder
(MDD) with (semi)structured interviews to estab-
lish DSM criteria reported higher prevalences than
those employing DSM criteria without a structured
interview7, 19. Depressive symptoms probably are
even more prevalent (in some studies above 75%)
among patients with PD and concomitant demen-
tia7, 23.
Even and Weintraub (2012) identified three
potential subtypes of depression in PD. Authors
took as a basis the 19% prevalence rate of major
depression in PD – a figure comes from studies
using a (semi) structured interview to establish
DSM criteria and reported by the systematic review
by Reijnders et al.19 – and other sources of preva-
lence data and calculated that 10.2% of depression
cases is specifically associated with PD (i.e. these
are those cases which are directly related to the pat-
hophysiology of PD). Another 6.8% of depression
cases observed among patients with PD are the con-
sequence of the chronic/debilitating nature of PD
(in other words these cases would be depressed if
they have another disabling comorbid medical ill-
ness). A third proportion (2%) of cases consists
those depressed subject who would be depressed
even if they would not suffer from PD24.
The majority of depressed patients with PD do
not receive antidepressant treatment, accordingly
we may state that depression is undertreated in this
patient population6, 25.
However, depressive symptoms frequently pre-
ceed the onset of motor signs of PD (discussed
below), in patients with already diagnosed PD the
onset of depression follows a bimodal distribution
(one peak in close proximity at the time of PD diag-
nosis and a second peak during the late course of
PD)7.
The distribution of the two main types of depres-
sion encountered in PD are: (1) about half of
depressed patients with PD meet the criteria for
major depressive episode (almost in all cases unipo-
lar major depression), and (2) another half have
minor depressive disorder or its chronic form called
dysthymic disorder8–10.
The diagnosis of depression in PD can be diffi-
cult owing to the overlap of symptoms between
depression, parkinsonism and cognitive symptoms,
and due to psychological reactions to the movement
disorder (e.g. fatigue may occur in both MDD and
PD; masklike/expressionless face may be interpre-
ted as affective blunting; bradykinesia may be inter-
preted as psychomotor retardation, a DSM criterion
for major depressive episode)1, 22, 23, 26. It is impor-
tant that the assessment of depression in patients
with motor fluctuations should be conducted during
“on” states. It should be remarked – apropos of this
issue – that, those patients with motor fluctuations
who have depressive symptoms only during the
“off” phases can be classified as having subsyndro-
mal depression and the treatment of their depressi-
ve symptoms should be initated with the adjustment
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of antiparkinsonian medications6, 13, 27, 28. Depression
associated with PD shows some clinical differences
from primary major depressive episode: in the
comorbid cases there are high levels of dysphoria,
anxiety, pessimism, irritability and suicidal
ideation. However, on the other hand, guilt, self-
blaming, marked fluctuations of mood and psychot-
ic features as well as attempted suicide and com-
pleted suicide are rare9, 10, 26, 28. Besides the detailed
interview based on ICD-10 or unmodified DSM-IV
criteria, the Geriatric Depression Scale (15-item
version) may be optimal because it is short, reliable
and less dependent on physical symptoms4, 23, 26.
There are several consequences of depression in
PD. Accordingly, depression in PD patients is asso-
ciated with declining motor symptoms, cognitive
impairment, reduced QoL, increased disability, ele-
vated levels of psychiatric and medical comorbidity
(and consequential higher mortality), greater
health-care utilization, poorer adherence to treat-
ment, increased stress on caregivers, etc.6, 7, 19, 23, 29.
It is important to emphasize that the impact of dep-
ression on QoL of subjects with PD seems to be big-
ger than the impact of the motor aspects of the ill-
ness29, 30.
Risk factors for depression in PD and
depression as a risk factor for PD
The most common risk factors for depression in
patients with PD include female gender, previous
history of depressive illness, hypo- or bradykinesis,
gait instability, greater functional disability, greater
degree of left hemisphere involvement, and an ear-
lier age of onset of PD. However, the role of family
history of depressive and other psychiatric disor-
ders and the current age of the patient are ambigu-
ous9, 10, 30–32. Findings of other studies suggest that
general risk factors of depression are able to predict
75% of depression cases in PD and from neurologi-
cal signs only the inclusion of the right-sided onset
of PD symptoms was able to enhance the efficacy
of prediction. Accordingly it was concluded that
there is a substantial overlap between established
risk factors for depression in the general population
and risk factors for depression among patients with
PD7. Results of a very recent study also suggest that
non-PD specific risk factors for depression are in a
3-times-stronger association with depression in PD
than PD-specific risk factors. Accordingly, they
found that six non-PD specific risk factors (female
sex, history of anxiety and/or depression, family
history of depression, worse functioning on activiti-
es of daily living, and worse cognitive status) and
three PD-specific variables (increased disease dura-
tion, more severe motor symptoms, the use of levo-
dopa) were associated with depression30.
It is important to note that in about 25% of cases
patients had already been depressed before the onset
of PD21, 33.
On the other hand, it has been also shown that
either depression could be a risk factor for PD or
PD and depression may have a common biologi-
cal/genetic root. Results of a large-scale retrospec-
tive study from general practice suggested that
depression itself might also be a risk factor for PD:
19 out of the 1358 depressed patients (1.39%) later
developed PD, while the same figure among the
67.570 nondepressed subjects was 259 (0.38%)
indicating that the development of PD in depressed
patients was about three times more frequent than
in the case of nondepressed primary care patients11.
Several other studies also found that depression was
more frequent among those who later became ill
with PD than among those who did not7. A recently
published, large-scale, retrospective, matched
cohort study found that among patients with depres-
sion the risk of developing PD is higher than among
control subjects and this association remained sig-
nificant even after the exclusion of those patients
whose depression was diagnosed ‘shortly’ (2-5
years) before the onset of PD. This result further
suggests that depression is an independent risk fac-
tor for PD34. In addition, increased risk of depressi-
on in first-degree relatives of PD patients suggests
that depression may share familial susceptibility
factors (genetic or nongenetic) with PD35, 36.
Pathophysiology of depression in
patients with PD
The pathophysiology of depression in PD is com-
plex and multicausal. Earlier aetiological models
have suggested that the development of depression
in PD was mainly a simple psychological reaction
to the severe physical disability caused by the
movement disorder. However, Robins (1976)
reported much higher rates of depression among
patients with PD than in a group of age and sex-
matched patients with the same level of physical
disability of neurological or orthopaedic causes
(hemiplegia, paraplegia, arthritis etc.) and others –
with some exceptions28 – also reported higher lev-
els of depression among patients with PD than
among individuals with other serious disorders of
the CNS (e.g. stroke) or other chronic and disabling
disorders5 ,6, 24, 37, 38. These findings refute the above
mentioned (“psychological reaction”) hypothesis
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and strongly suggests that depression (or at least the
bigger part of depression cases—see Even and
Weintraub, 2012) is a more integrant part of PD
indicating that the mood disturbance might be more
closely related to the brain (neurotransmitter)
pathology, i.e. that depression is the direct result of
underlying biochemical changes caused by the dis-
ease process9, 10, 12, 21. The exact cause of depression
in PD is still unknown, but it is very likely that the
aetiology is multifactorial and the role of psychoso-
cial factors also cannot be ruled out.
It is well known that a variety of subcortical
structures (substantia nigra pars compacta, ventral
tegmental area, nucleus basalis of Meynert, raphe
nuclei, locus coeruleus, etc.) which are also the
major sources of some neurotransmitters – those
very ones play an important role in the pathophysi-
ological background of primary depressive disor-
ders – are affected in PD. The pathological involve-
ment of these subcortical structures leads to altered
neurotransmitter (mainly dopamine, norepineph-
rine, serotonin and acethylcholine) signaling at sites
remote from these nuclei resulting in various
changes in levels of neurotransmitter metabolites,
receptors and transporters – in a somewhat similar
manner to those changes described consistently in
primary depressive disorders without any medical
comorbidity – and ultimately in depression1, 7, 26, 36,
39, 40–42. However it seems that results on changes of
the serotonergic system in PD-associated depres-
sion are less consistent (or more contradictory) than
in primary depressive disorders24, 26, 36. This is con-
sonant with those results which indicated that effi-
cacy of SSRI therapy in PD-associated depression
is limited (if it has any effect at all)29, 36.
In PD the neuropathological changes in areas
implicated in depression including the raphe nuclei
and the locus coeruleus may precede the loss of
dopaminergic neurons which may explain the phe-
nomena discussed above that some non-motor
symptoms of PD (including depression) frequently
occur prior to the appearance of motor symptoms5,
43, 44.
Therapy of depression in PD
ANTIPARKINSONIAN DRUGS
It has been demonstrated that some antiparkinson-
ian drugs as dopamine-receptor agonists (especial-
ly demonstrated in case of pramipexole and less for
bromocriptine) and MAO-B inhibitors (selegiline
and rasagiline), when administered in the recom-
mended dose-range for the treatment of PD exert
limited antidepressant efficacy in patients with PD.
The effects of other antiparkinson medications on
depressive symptoms are contradictiory. For exam-
ple, there are results on both mood improving and
mood deteriorating effects of L-DOPA. Mood
effects of anticholinergic drugs and amantadine are
considered as not clinically significant7, 9, 10, 25, 26,
44–47. Therefore, manipulation of these drugs is rec-
ommended as the first step in the pharmacological
treatment of depression in PD, and, if ineffective,
specific antidepressive pharmacotherapy is indicat-
ed (see below).
Selegiline (l-deprenyl), a selective MAO-B inhibitor, is
employed as a part of the treatment of PD, but it does not appear
to have a marked effect on depression in doses at which this
selectivity is present (less than 15 mg/day). However, in higher
doses (25 mg/day or above), selegiline loses its MAO-B selec-
tivity and starts to act as a nonselective MAO-I, inhibiting the
degradation not only of dopamine, but also of serotonin and
noradrenaline and works as an effective antidepressant48, 49. Of
course dietary restrictions are highly recommended if selegi-
line is administered in higher doses than the dose indicated in
the labeling.
ANTIDEPRESSANTS AND OTHER PSYCHOTROPIC AGENTS
Although depression in PD is very frequent and it
has deteriorating impact on QoL of the patient as
well as on the course of PD there is a scarcity of
well-designed treatment studies with antidepres-
sants in this patient population 7. Furthermore,
results of studies are frequently contradictory and –
accordingly – conclusions of meta-analyses are also
disillusioning29, 50.
The most prescribed subfamily of antidepres-
sants in PD is SSRIs24, 36. Earlier a few uncontrolled
studies14, 51–53 indicated that SSRI treatment is effec-
tive in the treatment of PD-associated depression7.
Until recently there was only limited and ambiguo-
us evidence from placebo-controlled studies rela-
ting to the efficacy of SSRIs (e.g. citalopram, sert-
ralin and paroxetine) in this patient population36.
However, a recent randomized, double-blind, pla-
cebo-controlled study by Richard et al. with 12
weeks duration compared the SSRI paroxetine, the
SNRI venlafaxine XR and placebo for patients with
PD with DSM-IV defined major or minor depressi-
on (n=115) and found that both medications have
significant benefits compared to placebo, without
worsening the motor symptoms36, 54, 55. At the same
time, results of the most recent meta-analysis –
which also includes the study by Richard et al.54 –
on efficacy of SSRIs in this patient population are
not convincing29. They also mentioned that antidep-
ressants in general and SSRIs in particular showed
statistically significant higher rates of dropouts than
placebo, but they appended that “in general antidep-
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ressant medications were well tolerated”29.
However there is a concern about the possible neg-
ative effect on SSRIs on PD-related motor symp-
toms (since serotonin has an inhibitory effect on the
dopamine release in the striatum) data are reassur-
ing in this regard7, 23, 29, 51, 53, 56.
Traditional tricyclic antidepressants (TCAs),
such as amitriptyline, imipramine, desipramine,
nortriptyline have all been shown to be effective in
the treatment of depression in patients with PD
(according to some opinions the efficacy of
desipramine and nortriptyline is more strongly con-
firmed than the efficacy of the remaining TCA
agents). There are some evidences that TCAs are
more effective than SSRIs for the treatment of
depression in PD6, 8–10, 23, 25, 29, 57, 58. At the same time,
due to their anticholinergic properties TCAs have
the propensity to impair some PD-related symptoms
such as cognitive and autonomic dysfunctions so
they should be used with caution5, 7, 26.
However, – from a theoretical point of view –
great caution and close monitoring are advised
when a MAO inhibitor (selegiline, rasagiline) is
coadministered with an agent with serotonin reup-
take inhibitory properties (e.g. SSRI; SNRI; TCA),
current results suggest a very low frequency of con-
sequential serotonin syndrome5, 7, 14, 57, 59.
Mirtazapine, atomoxetine and – interestingly –
buproprion, a norepinephrine-dopamine reuptake
inhibitor antidepressant, are not effective (or yet
little studied) in treating depression in patients with
PD 4,7,13,23,36. A double-blind, placebo-controlled
study of 31 subjects reported that fish oil (omega-3-
fatty acid) was effective in the treatment of major
depression comorbid with PD. Because of the safe
nature of fish oil this option may be a useful additi-
on to treatment, but further confirmation of this sin-
gle result is required by investigations with larger
sample sizes23, 58, 60.
OTHER THERAPEUTIC MODALITIES
Electroconvulsive therapy (ECT) might also be an
effective treatment of depressed patients with PD,
particularly in drug intolerant or drug resistent
cases7, 9. In addition, ECT has beneficial effects on
motor symptoms of PD which are independent of
its impacts on depressive symptoms and occurred
well before these7, 61.
Some findings also suggest that the use of ECT
is probably safe in patients with STN-DBS electro-
des in place. This may be of great importance, since
depression with an increased risk of suicide is fre-
quent following DBS surgery7, 62.
Results on the impact of deep brain stimulation
(DBS) – an intervention with well-established effi-
cacy in alleviating motor dysfunction and drug-
associated motor side effects and allowing dopami-
nergic dose reduction in PD – on depression in PD
are ambiguous: while some findings suggest that
STN-DBS (the only treatment modality of PD which
– according to recent preliminary data – seems to
improve survival of patients) amends depressive
symptoms associated with PD (moreover it leads to
mania in some cases) others found that it is also
associated with depression and substantially elevat-
ed risk of suicide postoperatively5, 7, 25, 63, 64.
However, DBS treatment of some other targets than
subthalamic nuclei (e.g. globus pallidus) has been
rarely reported to be associated with mood-
changes6, 6–67.
According to our best knowledge so far only a
few studies investigated the efficacy of repetitive
transcranial magnetic stimulation (rTMS) – a
noninvasive brain stimulation method, which has
already been proven effective for the treatment of
idiopathic major depression – among patients with
depression and PD. These studies provided promi-
sing results and found that treatment is well-tolera-
ted in this patient population but further multi-cen-
tered studies involving larger samples and using
double-blinded, sham-controlled design are needed
before rTMS become an established treatment for
depression associated with PD36, 68–70.
The efficacy of cognitive behavioural therapy
(CBT) was evaluated recently by two studies in
Parkinson’s disease depression71, 72. In the first
study authors used an RCT setting and found that
CBT (modified to meet the unique needs of patients
with PD) administred for 10 weeks was associated
with a significantly greater reduction in depression
scores than clinical monitoring only (i.e. the place-
bo condition). Furthermore, the CBT group also
reported greater improvements on secondary outco-
me measures (e.g. QoL, coping and anxiety as well
as motor symptoms)4, 23, 71. The same authors confir-
med their results in a second uncontrolled pilot
study using telephone-based CBT intervention
(which may be especially valuable in this populati-
on because of their difficulties in movement).
Results of this study are also promosing23, 72.
Other antidepressant treatments, such as sleep
deprivation as well as light therapy are not well
studied in PD and warrant further investigations.
Discussion
Depression is a common nonmotor feature of PD
which frequently remains unrecognised and untreat-
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ed. Adverse impacts of comorbid depression in pati-
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